Vanguard Personalized Indexing Management LLC Has $601,000 Holdings in Genmab A/S (NASDAQ:GMAB)

Vanguard Personalized Indexing Management LLC increased its stake in shares of Genmab A/S (NASDAQ:GMAB) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,914 shares of the company’s stock after purchasing an additional 338 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Genmab A/S were worth $601,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. First Manhattan Co. acquired a new stake in shares of Genmab A/S during the fourth quarter worth $26,000. Belpointe Asset Management LLC acquired a new position in Genmab A/S in the fourth quarter valued at about $86,000. Atlas Capital Advisors LLC increased its holdings in shares of Genmab A/S by 176.4% in the fourth quarter. Atlas Capital Advisors LLC now owns 2,488 shares of the company’s stock worth $105,000 after acquiring an additional 1,588 shares in the last quarter. Captrust Financial Advisors increased its holdings in shares of Genmab A/S by 62.0% in the first quarter. Captrust Financial Advisors now owns 2,658 shares of the company’s stock worth $96,000 after acquiring an additional 1,017 shares in the last quarter. Finally, FNY Investment Advisers LLC bought a new stake in shares of Genmab A/S in the first quarter worth about $151,000. 6.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GMAB has been the subject of several recent analyst reports. HSBC initiated coverage on Genmab A/S in a report on Friday, July 14th. They issued a “buy” rating for the company. BTIG Research initiated coverage on Genmab A/S in a report on Thursday. They issued a “buy” rating for the company. Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a report on Monday, July 31st. UBS Group initiated coverage on Genmab A/S in a report on Wednesday, May 31st. They issued a “neutral” rating for the company. Finally, HC Wainwright reiterated a “buy” rating on shares of Genmab A/S in a report on Tuesday, August 15th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $932.50.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB opened at $37.43 on Friday. The stock has a 50 day moving average price of $38.50 and a 200 day moving average price of $38.84. Genmab A/S has a 52 week low of $31.40 and a 52 week high of $47.50. The stock has a market capitalization of $24.72 billion, a PE ratio of 37.43, a price-to-earnings-growth ratio of 2.22 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 3rd. The company reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.01). Genmab A/S had a net margin of 28.78% and a return on equity of 16.93%. The business had revenue of $613.43 million during the quarter, compared to analyst estimates of $618.77 million. As a group, research analysts forecast that Genmab A/S will post 1.02 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.